MAFB and COVID-19: Since pathogenic lung macrophages in severe COVID-19 exhibit high levels of inactive GSK3 and heightened levels of MAFB and MAFB-dependent proteins, our results underscore the potent macrophage reprogramming impact of GSK3 inhibition and highlight the GSK3-MAFB axis as a promising therapeutic target for macrophage reprogramming.